Results 181 to 190 of about 20,878 (216)

Ibrutinib combined with rituximab and high-dose methotrexate in newly diagnosed primary CNS diffuse large B-cell lymphoma: a pilot study with long-term follow-up. [PDF]

Front Oncol
Guo Y, Shan Y, Piao Y, Chang X, Zou D, Ma Q, Wei Y, Xu G, Wang Y, Wang D, Teng L, Wu C, Zhao Z, Song T, Zhao H, Hui W, Su L, Sun W.   +17 more
europepmc   +1 more source

The new Bruton's tyrosine kinase inhibitors SPA8007 and SPA8009 reduce stemness and invasiveness of patient-derived glioblastoma tumorspheres. [PDF]

Transl Oncol
Jo E, Lee E, Oh Y, Lee D, Lee B, Kim K, Choi RJ, Hong J, Jeon Y, Cho H, Choi YS, Kim S, Won SY, Choi S, Roh TH, Moon JH, Kim EH, Chang JH, Jeon R, Kang SG.   +19 more
europepmc   +1 more source

Advances in the combination of CAR-T therapy with small-molecule reagents for hematologic malignancies. [PDF]

Front Immunol
Yang B, Su Y, Wang C, Yu L.
europepmc   +1 more source

Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma. [PDF]

Int J Clin Oncol
Goto H, Ito S, Kizaki M, Yamaguchi M, Fukuhara N, Kato K, Saito T, Terui Y, Soshin T, Satomi-Tsushita N, Honda H, Qian C, Izutsu K.   +12 more
europepmc   +1 more source

B-cell receptor signaling and microenvironment crosstalk in mantle cell lymphoma. [PDF]

Cell Commun Signal
Quaglia FM, Gambino S, Galasso M, Vegliante MC, Visco C, Scupoli MT.   +5 more
europepmc   +1 more source

Chronic oral administration of ibrutinib prevents long-term memory deficits and reduces AD pathology and neuroinflammatory responses in a mouse model of AD. [PDF]

Mol Brain
Lee HJ, Kang S, Jeong YJ, Park JH, Hwang JW, Gu CH, Jung TM, Oh S, Jang JY, Hoe HS.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Ibrutinib

Reactions Weekly, 2018
Abnormal B-cell receptor (BCR) signalling is a key mechanism of disease progression in B-cell malignancy. Bruton's tyrosine kinase (BTK) has a pivotal role in BCR signalling. Ibrutinib (PCI-32765) is a small molecule which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency.
Andriani, Charalambous, Mark-Alexander, Schwarzbich, Mathias, Witzens-Harig   +2 more
  +7 more sources

Ibrutinib

2014
Abnormal B-cell receptor (BCR) signaling is a key mechanism of disease progression in B-cell malignancy. Bruton's tyrosine kinase (BTK) has a pivotal role in BCR signaling. Ibrutinib (PCI-32765) is a novel agent which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency.
Mark-Alexander, Schwarzbich, Matthias, Witzens-Harig   +1 more
openaire   +2 more sources

Ibrutinib

Reactions Weekly, 2022
  +8 more sources

Ibrutinib

Reactions Weekly, 2019
  +9 more sources